Calliditas Therapeutics AB

Activities: Pharmaceutical

Trending Articles

  1. Driving sustainable transition in pharmaceutical packaging The pharmaceutical industry, although dedicated to improving human health, is increasingly grappling with the challenge of balancing this mission with environmental...
  2. Blood plasma processing: when every drop counts Plasma derivatives obtained from human blood support the treatment of various diseases — from haemophilia and antigen defects to COVID-19. The products are in high demand and...
  3. Olon continues its growth with a new acquisition The acquisition of Huvepharma Italia Srl increases production capacity and expands market presence
  4. AI in IT/OT integration: how technology can overcome cybersecurity hurdles Manufacturing Chemist (MC) spoke to Rene Hackl (RH), Managing Director at Phytools about how artificial intelligence (AI) can revolutionise IT/OT integration
  5. Have you seen the latest from METTLER TOLEDO on advanced filling solutions? Join METTLER TOLEDO’s free webinar to explore weight-based filling for greater accuracy and control

Upcoming event

Pharmaconex

8-10 September 2024 | Conference | Cairo, Egypt See all

Related Content

Research & Development

Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon

China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression
Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Drug Delivery

Chinese NMPA accepts Calliditas' partner Everest Medicines NDA

Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people

Calliditas budesonide therapy approved to reduce proteinuria

Proteinuria is associated with IgAN, however it has not yet been established whether the therapy slows kidney function decline in patients with the condition
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing

Calliditas and Everest Medicines enter $120m development deal in China

The agreement gives Everest Medicines exclusive rights to develop and commercialise Nefecon in five countries in East Asia
Subscribe now